News

9 June 23

FDA advisers vote that lecanemab shows benefit as an Alzheimer’s treatment

‘’The Alzheimer’s drug lecanemab has received unanimous support from an advisory panel for the US Food and Drug Administration, which deemed it to have ‘clinical benefit’ for the treatment of the disease. This positive vote paves the way for the medication to be considered for full FDA approval. Lecanemab, known as Leqembi, is one of the first drugs that appears to slow cognitive decline in dementia patients by targeting amyloid beta. Patient groups and experts hope that this milestone decision will ensure access to FDA-approved therapies without barriers, similar to treatments for other serious conditions. The FDA is expected to announce its decision by July 6.’’

3 May 23

Third Amyloid plaque clearing drug against AD in two years is reason for hope

On May 3rd, 2023 Ely Lily announced positive results from their phase 3 clinical trial (TRAILBLAZER-ALZ2) for the drug, Donanemab, a monoclonal antibody (Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease, n.d.).

14 March 23

Simufilam aids cognition in 47% of Alzheimer’s patients in Phase 2 study

A Phase 2 clinical trial of simufilam, an experimental medication for Alzheimer’s disease, showed cognitive benefits in nearly half of the patients after one year of treatment. The medication was particularly effective for those in the early stages of the disease. Simufilam also demonstrated positive effects on depression and dementia-related behaviors. Phase 3 trials are currently enrolling participants to further investigate the safety and efficacy of simufilam. The goal is to develop an effective treatment for Alzheimer’s, a progressive disease characterized by memory loss, confusion, and cognitive decline.

16 January 23

Challenge your brain! Eight suggestions for brain-boosting exercises 

What does it mean to “challenge your brain”? Here are some suggestions! They may help you in keeping your brain fit, healthy and as protected as possible against the risk of dementia.

12 January 23

Your questions, answered: What should Canadians know about lecanemab’s U.S. FDA approval?

On January 6, 2023, the U.S. Food and Drug Administration approved the new drug Leqembi (also known as lecanemab) for treatment of early Alzheimer’s disease. Here’s what people in Canada might want to know about it.

Gatineau

Les jasettes du premier jeudi : L’aide médicale à mourir

Gatineau

Les jasettes du premier jeudi : Trucs et astuces pour des impôts bien réussis

Montréal

Le Salon Carrefour 50 ans +